In an earlier post, I pointed out that ADT is immuno-protective:
healthunlocked.com/advanced...
Some members pointed out that immunoprotection may not be useful against Covid-19. Now an Italian observational study suggests that it is. Men with PCa not taking ADT were 4 times as likely to be diagnosed with Covid-19 and also with serious cases of Covid-19. Was that because people with cancer took more care? Apparently not - people with other cancers were 5 times as likely to be diagnosed with Covid-19.
The effect was very big - only 4 of 5,273 men on ADT were covid-19 positive (none died) , but 114 men of 37,161 men with PCa who were not on ADT were covid-19 positive (18 died). Among 79,661 patients with other types of cancer, 312 developed COVID-19 (57 died).
Because men are much more likely to die of Covid-19 than women, and the protective effect appears to be so strong, the authors suggest that men who are at high risk of infection (and who do not have PCa), use a short-acting form of ADT (like Firmagon) to protect them from infection.